PAI
Palo Alto Investors Portfolio holdings
AUM
$470M
This Quarter Return
+3.08%
1 Year Return
+2.57%
3 Year Return
+93.77%
5 Year Return
+190.64%
10 Year Return
+955.02%
AUM
$1.24B
AUM Growth
+$1.24B
(+2.5%)
Cap. Flow
+$28.2M
Cap. Flow
% of AUM
2.28%
Top 10 Holdings %
Top 10 Hldgs %
87.1%
Holding
32
New
2
Increased
4
Reduced
3
Closed
2
Top Buys
| 1 |
NovoCure
NVCR
|
$22.6M |
| 2 |
Sarepta Therapeutics
SRPT
|
$10.8M |
| 3 |
NVRO
NEVRO CORP.
NVRO
|
$4.73M |
| 4 |
STAAR Surgical
STAA
|
$1.45M |
| 5 |
Relmada Therapeutics
RLMD
|
$468K |
Top Sells
| 1 |
PRVB
Provention Bio, Inc. Common Stock
PRVB
|
$9.42M |
| 2 |
RVNC
Revance Therapeutics, Inc.
RVNC
|
$1.05M |
| 3 |
Vanda Pharmaceuticals
VNDA
|
$1.05M |
| 4 |
Prothena Corp
PRTA
|
$431K |
| 5 |
PKBO
Peak Bio, Inc. Common Stock
PKBO
|
$314K |
Sector Composition
| 1 | Healthcare | 98.22% |
| 2 | Financials | 1.78% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
BioMarin Pharmaceuticals
BMRN
$11.2B
| $159M | 12.82% | 1,831,035 | – | – |
|
2
United Therapeutics
UTHR
$13.8B
| $139M | 11.19% | 627,514 | – | – |
|
|
RVNC
3
DELISTED
Revance Therapeutics, Inc.
RVNC
| $132M | 10.69% | 5,228,609 -41,600 | -0.8% | -$1.05M |
|
4
Amicus Therapeutics
FOLD
$2.34B
| $132M | 10.68% | 10,524,022 | – | – |
|
5
Insmed
INSM
$28.8B
| $124M | 10.04% | 5,889,491 | – | – |
|
|
6
Prothena Corp
PRTA
$441M
| $113M | 9.14% | 1,657,458 -6,319 | -0.4% | -$431K |
|
7
Biogen
BIIB
$19.4B
| $109M | 8.77% | 381,282 | – | – |
|
|
8
STAAR Surgical
STAA
$1.36B
| $72.3M | 5.84% | 1,374,822 +27,500 | +2% | +$1.45M |
|
9
Acadia Pharmaceuticals
ACAD
$4.38B
| $57.6M | 4.65% | 2,405,793 | – | – |
|
|
SAGE
10
DELISTED
Sage Therapeutics
SAGE
| $40.4M | 3.27% | 859,517 | – | – |
|
11
Align Technology
ALGN
$10.3B
| $26.4M | 2.13% | 74,605 | – | – |
|
|
12
NovoCure
NVCR
$1.38B
| $24M | 1.94% | 578,118 +545,328 | +1,663% | +$22.6M |
|
13
eHealth
EHTH
$118M
| $22M | 1.78% | 2,739,379 +50,000 | +2% | +$402K |
|
14
Alkermes
ALKS
$4.78B
| $18.9M | 1.53% | 603,400 | – | – |
|
15
Syndax Pharmaceuticals
SNDX
$1.41B
| $12.8M | 1.04% | 612,600 | – | – |
|
|
16
Sarepta Therapeutics
SRPT
$1.78B
| $10.8M | 0.87% | +94,030 | New | +$10.8M |
|
17
Karyopharm Therapeutics
KPTI
$61.7M
| $10.2M | 0.82% | 5,675,876 | – | – |
|
18
AnaptysBio
ANAB
$569M
| $8.77M | 0.71% | 431,224 | – | – |
|
|
NVRO
19
DELISTED
NEVRO CORP.
NVRO
| $4.73M | 0.38% | +186,259 | New | +$4.73M |
|
20
Gossamer Bio
GOSS
$562M
| $4.16M | 0.34% | 3,465,152 | – | – |
|
21
Cytokinetics
CYTK
$4.23B
| $3.64M | 0.29% | 111,717 | – | – |
|
22
Travere Therapeutics
TVTX
$1.56B
| $2.55M | 0.21% | 166,069 | – | – |
|
|
23
Vanda Pharmaceuticals
VNDA
$279M
| $2.14M | 0.17% | 324,073 -158,624 | -33% | -$1.05M |
|
|
24
Relmada Therapeutics
RLMD
$37.2M
| $1.8M | 0.15% | 732,400 +190,300 | +35% | +$468K |
|
25
Mirum Pharmaceuticals
MIRM
$3.71B
| $1.67M | 0.14% | 64,700 | – | – |
|